Best Genomics Companies in Rockville, United States
The 30 best Genomics companies in Rockville, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: OpGen.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Rockville
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OpGen Developer of diagnostics and bioinformatics platforms for providers | $78M | 68 mo ago | 100 | — | Public | WordPressMySQLPHP+16 | 110 patents Microbial genomic analysis for antibiotic resistance detection and susceptibility testing | — |
| 2 | OriGene Provider and manufacturer of proteins, antibodies, and other molecular tools for research applications | $70M | 137 mo ago | 141 141 → 130 (-8%) | — | Series D | Cart FunctionalityMagentoMySQL+34 | 14 patents Protein array platforms for biomarker detection, antibody specificity, and disease diagnostics | — |
| 3 | Synthetic Biologics Developing oncolytic virus therapies to overcome solid tumor barriers | $31M | 51 mo ago | 21 | — | Late Stage | — | 208 patents Microbiome-protective enzyme therapeutics and engineered microbial production platforms | — |
| 4 | Innovative Biosensors Developer of self-contained biosensor system for rapid diagnostic tests | $20M | 176 mo ago | 1 | — | Series B | — | — | — |
| 5 | Vigene Biosciences Developer of life science research reagents for drug discovery and functional genomics | $10M | 79 mo ago | 45 | Zairen Sun CEO | Acquired | — | — | — |
| 6 | CosmosID Developer of next-generation sequencing (NGS) technologies for the detection of microorganisms | $7M | 89 mo ago | 7 | — | Series B | WordPressMySQLPHP+23 | 33 patents Microbial genome identification and quantification using anchor-based bioinformatics data structures. | — |
| 7 | BioMarker Strategies Develops Cancer Diagnostics System | $7M | 110 mo ago | 8 | Jerry Parrott President | Series A | — | 42 patents Predictive biomarkers and methods to overcome resistance in cancer immunotherapy. | — |
| 8 | Creatv Bio Developer of blood based tests for treating cancer | $4M | 86 mo ago | 9 | — | Funding Raised | — | — | — |
| 9 | Silvec Developer of RNA-based genetic breeding solutions for plants | $2M | 17 mo ago | 26 26 → 13 (-50%) | Anne Simon Co-Founder | Funding Raised | — | — | — |
| 10 | Polaris Genomics Developer genomic-based diagnostics and therapeutics for neurological conditions | $800K | 15 mo ago | 10 | Tshaka Cunningham Co-Founder | Series A | — | — | — |
| 11 | Full Genomes Consumer facing genome sequencing company | $602K | 92 mo ago | 3 | Paul Conroy Founder & Director | Public | — | — | — |
| 12 | HepC Developer of antiviral biologic products | $400K | — | — | Thomas Bakacs CEO | Funding Raised | — | — | — |
| 13 | Rise Therapeutics Developer of targeted immunological-based biologics for gastrointestinal (GI) inflammatory disease | $200K | 18 mo ago | 10 | Neil Fanger Co-Founder | Seed | — | — | — |
| 14 | Cellomics Technology Provider of products and services to genetically engineer mammalian somatic and stem cells | $150K | 163 mo ago | 4 | — | Seed | Cart FunctionalityBootstrapMicrosoft ASP.NET+7 | 116 patents AI-driven automated microscopy and image analysis for cell counting and fluorescence imaging | — |
| 15 | Ariadne Diagnostics Developer of diagnostic tests for oncology and neurodegenerative diseases | $100K | 160 mo ago | 5 | Ilya Mazo Co-Founder & CEO | Seed | — | — | — |
Top 12 Genomics companies in Rockville
#1
Funding Raised · Rockville, Maryland · founded 2019 · 26 employees$1.6Mraised▾
Developer of RNA-based genetic breeding solutions for plants. It offers genetic modification in plants to protect them against diseases. It offers solutions for trees, vines, and bushes.
- Jun 2025Grant (prize money)$98K
- Mar 2025Grant (prize money)$256.5K
- Sep 2023Grant (prize money)$650K
- May 2022Grant (prize money)$175K
#2
Series A · Rockville, Maryland · founded 2017 · 10 employees$800Kraised▾
Developer genomic-based diagnostics and therapeutics for neurological conditions. The company uses a proprietary bioinformatics engine TruNorth Platform for Neuropsychiatric genomic analysis. Also, it develops PTS-ID a genomic test for the diagnosis and treatment of Post-traumatic stress disorder.
- Aug 2025Conventional Debt$250K
- Oct 2023Conventional Debt$1M
- May 2023Conventional Debt$1M
- Feb 2021Conventional Debt$100K
#3
Seed · Rockville, Maryland · founded 2016 · 10 employees$200Kraised▾
Developer of targeted immunological-based biologics for gastrointestinal (GI) inflammatory disease. It offers oral delivery platform, TriPartite X (TPX) is a novel DNA assembly approach that allows for the creation of recombinant probiotics to escort targeted protein therapies to the intestinal space. Its drug pipeline includes R-2487, an immunobiotic drug that can cause autoimmunity in tissues distal from the intestinal tract; R-3750 which is being developed for the treatment of gastrointestinal (GI) inflammatory disease.
- May 2025Grant (prize money)$2.9M
- Apr 2025Grant (prize money)$2.1M
- Mar 2025Grant (prize money)$2.1M
- Mar 2025Grant (prize money)$2.9M
#4
Public · Rockville, Maryland · founded 2002 · 100 employees$77.5Mraised▾
Developer of diagnostics and bioinformatics platforms for providers. The company’s lead product is the Acuitas MDRO Gene Test. Other products include the Acuitas Lighthouse MDRO Management System and the Acuitas Resistome Test. The company’s products and services are designed to enable the identification of hospital patients who are infected with multi-drug resistant organisms, or MDROs.
- Feb 2021Post IPO$25M
- Dec 2020Post IPO$10M
- Jul 2018Post IPO$285.5K
- Sep 2017Post IPO$110K
#5
Late Stage · Rockville, Maryland · founded 1986 · 21 employees$31.4Mraised▾
Developing oncolytic virus therapies to overcome solid tumor barriers. This clinical-stage immuno-oncology company focuses on developing oncolytic viruses designed to selectively kill tumor cells and overcome the protective barriers surrounding solid tumors. Their developmental therapies aim to enable systemic delivery and enhance current standard-of-care treatments, offering the potential for longer lives for patients with difficult-to-treat cancers. The company's engineered oncolytic viruses offer a powerful approach to treating therapeutically challenging cancers, overcoming the limitations of traditional oncolytic viruses. They are exploring technologies to expand their therapeutic approach and combine their viruses with a variety of cancer therapies. The company seeks to transform the cancer therapy landscape through innovative solutions in the biotechnology and pharmaceutical industries.
- Jul 2022Post IPO$3M
- Sep 2017Post IPO$12M
- Sep 2013Grant (prize money)$5.6M
- Nov 2012Post IPO$10.8M
#6
Series D · Rockville, Maryland · founded 1996 · 141 employees$69.6Mraised▾
OriGene Technologies is focused on developing proteins, antibodies, and other molecular tools to support the academic, pharmaceutical, and biotech companies in their research of gene functions and drug discovery. Its product lines include the large cDNA and shRNA clone collections, about 5k purified human proteins, monoclonal antibodies (TrueMAB), 140k validated human tissues, and protein microarray products. It also provides a range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from the Company's tissue collection.
- Jun 2015Series D$17.1M
- Mar 2014Series C$200K
- Mar 2013Series C$21.3M
- Sep 2012Series B$15M
#7
Series B · Rockville, Maryland · founded 2003 · 1 employees$20.4Mraised▾
Innovative Biosensors is a developer of a self-contained biosensor system for rapid diagnostic tests. It has developed technology that is a genetically engineered biosensor that allows for extremely rapid testing of analytes, providing high levels of sensitivity and specificity. The patented, self-contained biosensor system is capable of generating a sensitive and specific result with minimal amount of reagents in minutes, making it a cost-effective alternative to traditional laboratory testing. The biosensors can be engineered to detect one target or several targets of interest simultaneously and used to perform a wide variety of bioassays. Designed for real-time detection, minimally-skilled personnel can perform tests and analysis at the site of sampling using small, portable, space-saving instrumentation.
- Mar 2012Series B$1.5M
- Mar 2010Series B$3.9M
- May 2008Series B$9.5M
- May 2008Conventional Debt$2M
#8
Acquired · Rockville, Maryland · founded 2012 · 45 employees$10.5Mraised▾
Developer of life science research reagents for drug discovery and functional genomics. Its product portfolio includes adeno associated virus (AAV), lentivirus, human cDNA clones, mammalian expression vector, and molecular bioreagents. Its services include Plasmid, Adenoviral, Lentiviral Cloning, AAV packaging Service, TALE Nuclease, and shRNA Cloning service.
- Mar 2020Series A$3M
- May 2019Series A$7.5M
#9
Series A · Rockville, Maryland · founded 2007 · 8 employees$7.3Mraised▾
BioMarker Strategies develops Cancer Diagnostics System. The company has developed SnapPath that is a Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Its PathMAP functional signaling profiles, created using the SnapPath system, provide a new class of biomarker tests that are highly predictive of individual response for targeted treatments of solid tumors.
- Sep 2017Grant (prize money)$299.3K
- Aug 2016Series A$525K
- Jul 2016Grant (prize money)$2.3M
- Sep 2015Grant (prize money)$2.3M
#10
Series B · Rockville, Maryland · founded 2008 · 7 employees$7.3Mraised▾
Developer of next-generation sequencing (NGS) technologies for the detection of microorganisms. The company's GENIUS software suite employs CosmosID’s curated genome database and utilizes proprietary algorithms to obtain, bacterial identification at the species, subspecies, and/or strain level. The company claims that the turnaround time is just a few minutes.
- 2019Series B—
- Jan 2016Series B$6M
- Sep 2011Series A$100K
- Aug 2011Series A$1.2M
#11
Funding Raised · Rockville, Maryland · founded 2020 · 9 employees$4.2Mraised▾
Creatv has developed liquid cell biopsy-based test for cancer detection. The company has developed CellSieve microfiltration system to isolate the cancer cells from blood by identifying the cancer-associated macrophage-like cell (CAML) biomarker and enable the development of precision medicines.
- Sep 2019Grant (prize money)$197K
- Sep 2018Grant (prize money)$2.4M
- Sep 2018Grant (prize money)$297.3K
- Jul 2018Grant (prize money)$625K
#12
Public · Rockville, Maryland · founded 2012 · 3 employees$602.1Kraised▾
Full Genomes uses sequencing technology to provide services such as reports on a customer's ancestry, genealogy, and family history, using full sequencing of the Y chromosome as well as other products. Also provides access to an extensive database of next generation sequencing reports. Allows users to purchase kits online and send it back to the lab. Gets results online.
- Mar 2019Seed$25K
- Aug 2018Seed$187.9K
- May 2016Seed$19.1K
- Oct 2015Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising